Comparing the impact of upfront radiosurgery versus expectation in vestibular schwannoma (the V-REX study): protocol for a randomised, observer-blinded, 4-year, parallel-group, single-centre, superiority study

Dhanushan Dhayalan, Øystein Vesterli Tveiten, Frederik Kragerud Goplen, Monica Katrine Finnkirk, Anette Margrethe Storstein, Eli Renate Gruner, Morten Lund-Johansen, Dhanushan Dhayalan, Øystein Vesterli Tveiten, Frederik Kragerud Goplen, Monica Katrine Finnkirk, Anette Margrethe Storstein, Eli Renate Gruner, Morten Lund-Johansen

Abstract

Introduction: The optimal management of small-sized to medium-sized vestibular schwannoma (VS) is a matter of controversy. Clinical results of the prevailing treatment modalities (microsurgery, stereotactic radiosurgery (SRS), and conservative management (CM)) are documented, but comparative studies are few, and none are randomised or blinded. Upfront radiosurgery, or a careful follow-up by MRI with subsequent treatment on growth, are two strategies used at many centres. The present study aims at comparing these strategies by randomising individuals with newly diagnosed tumours to either upfront SRS or initial CM.

Methods and analysis: The Vestibular Schwannoma: Radiosurgery or Expectation study is designed as a randomised, controlled, observer-blinded, single-centre superiority trial with two parallel groups. Eligible patients will be randomised using sequentially numbered opaque sealed envelopes, and the radiosurgery group will undergo standard Gamma Knife Radiosurgery (GKRS) within 2 months following randomisation. The primary endpoint is tumour growth measured as volume ratio V4years/Vbaseline and volume doubling time, evaluated by annual T1 contrast MRI volumetric analysis. Secondary endpoints include symptom and sign development measured by clinical examination, audiovestibular tests, and by patient's responses to standardised validated questionnaires. In addition, the patient's working status, and the health economics involved with both strategies will be evaluated and compared. All outcome assessments will be performed by blinded observers. Power analysis indicates that 100 patients is sufficient to demonstrate the effect of GKRS on tumour volume.

Ethics and dissemination: The trial has ethical approval from the Regional Ethical Committee (23503) and funding from The Western Norway Regional Health Authority. Trial methods and results will be reported according to the Consolidated Standards of Reporting Trials 2010 guidelines in a peer-reviewed journal.

Trial registration number: Clinical trials: NCT02249572. Haukeland University Hospital record: 2014/314. Regional Ethical Committee (REC West): 23 503. The Western Norway Regional Health Authority: 912 281.

Keywords: head & neck tumours; magnetic resonance imaging; neurosurgery; neurotology; radiotherapy.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Hearing acuity as suggested endpoint.
Figure 2
Figure 2
Hearing acuity as suggested endpoint.
Figure 3
Figure 3
Hearing acuity as suggested endpoint.
Figure 4
Figure 4
Tumour size as the suggested endpoint.
Figure 5
Figure 5
The Smartbrush function iPlan Brainlab Elements provide an interactive method for three-dimensional object creation by outlining an area on each image slice.

References

    1. Jacob A, Robinson LL, Bortman JS, et al. . Nerve of origin, tumor size, hearing preservation, and facial nerve outcomes in 359 vestibular schwannoma resections at a tertiary care academic center. Laryngoscope 2007;117:2087–92. 10.1097/MLG.0b013e3181453a07
    1. Myrseth E, Møller P, Pedersen P-H, et al. . Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 2009;64:654–61. 10.1227/01.NEU.0000340684.60443.55
    1. Stangerup S-E, Tos M, Thomsen J, et al. . True incidence of vestibular schwannoma? Neurosurgery 2010;67:1335–40. 10.1227/NEU.0b013e3181f22660
    1. Foley RW, Maweni RM, Jaafar H, et al. . The impact of primary treatment strategy on the quality of life in patients with vestibular schwannoma. World Neurosurg 2017;102:111–6. 10.1016/j.wneu.2017.02.087
    1. Paldor I, Chen AS, Kaye AH. Growth rate of vestibular schwannoma. J Clin Neurosci 2016;32:1–8. 10.1016/j.jocn.2016.05.003
    1. Stangerup S-E, Caye-Thomasen P, Tos M, et al. . The natural history of vestibular schwannoma. Otol Neurotol 2006;27:547–52. 10.1097/01.mao.0000217356.73463.e7
    1. Varughese JK, Breivik CN, Wentzel-Larsen T, et al. . Growth of untreated vestibular schwannoma: a prospective study. J Neurosurg 2012;116:706–12. 10.3171/2011.12.JNS111662
    1. Breivik CN, Nilsen RM, Myrseth E, et al. . Working disability in Norwegian patients with vestibular schwannoma: vertigo predicts future dependence. World Neurosurg 2013;80:e301–5. 10.1016/j.wneu.2013.03.069
    1. Carlson ML, Tveiten OV, Driscoll CL, et al. . Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls. J Neurosurg 2015;122:833–42. 10.3171/2014.11.JNS14594
    1. Dhayalan D, Lund-Johansen M, Finnkirk M, et al. . Fatigue in patients with vestibular schwannoma. Acta Neurochir 2019;161:1809–16. 10.1007/s00701-019-04003-2
    1. Myrseth E, Moller P, Wentzel-Larsen T. Untreated vestibular schwannoma: vertigo is a powerful predictor for health-related quality of life. Neurosurgery 2006;59:67–76.
    1. Carlson ML, Habermann EB, Wagie AE, et al. . The Changing Landscape of Vestibular Schwannoma Management in the United States--A Shift Toward Conservatism. Otolaryngol Head Neck Surg 2015;153:440–6. 10.1177/0194599815590105
    1. Pollock BE, Driscoll CLW, Foote RL, et al. . Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery 2006;59:77–85. 10.1227/01.NEU.0000219217.14930.14
    1. Kondziolka D, Mousavi SH, Kano H, et al. . The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation? Neurosurg Focus 2012;33:E8. 10.3171/2012.6.FOCUS12192
    1. Niranjan A, Mathieu D, Kondziolka D, et al. . Radiosurgery for intracanalicular vestibular schwannomas. Prog Neurol Surg 2008;21:192–9. 10.1159/000156973
    1. Régis J, Carron R, Park MC, et al. . Wait-and-see strategy compared with proactive gamma knife surgery in patients with intracanalicular vestibular schwannomas. J Neurosurg 2010;113:105–11. 10.3171/2010.8.GKS101058
    1. Breivik CN, Nilsen RM, Myrseth E, et al. . Conservative management or gamma knife radiosurgery for vestibular schwannoma: tumor growth, symptoms, and quality of life. Neurosurgery 2013;73:48–56. 10.1227/01.neu.0000429862.50018.b9
    1. Myrseth E, Pedersen P-H, Møller P, et al. . Treatment of vestibular schwannomas. why, when and how? Acta Neurochir 2007;149:647–60. 10.1007/s00701-007-1179-0
    1. Nilsen KS, Lund-Johansen M, Nordahl SHG, et al. . Long-term effects of conservative management of vestibular schwannoma on dizziness, balance, and caloric function. Otolaryngol Head Neck Surg 2019;161:846–51. 10.1177/0194599819860831
    1. Link MJ, Lund-Johansen M, Lohse CM, et al. . Quality of life in patients with vestibular schwannomas following gross total or less than gross total microsurgical resection: should we be taking the entire tumor out? Neurosurgery 2018;82:541–7. 10.1093/neuros/nyx245
    1. Carlson ML, Tveiten Øystein Vesterli, Lund-Johansen M, et al. . Patient motivation and long-term satisfaction with treatment choice in vestibular schwannoma. World Neurosurg 2018;114:e1245–52. 10.1016/j.wneu.2018.03.182
    1. Tveiten OV, Carlson ML, Link MJ, et al. . Audiovestibular handicap and quality of life in patients with vestibular schwannoma and “excellent” hearing. Neurosurgery 2017;80:386–92. 10.1227/NEU.0000000000001238
    1. Tveiten Øystein Vesterli, Carlson ML, Goplen F, et al. . Patient- versus physician-reported facial disability in vestibular schwannoma: an international cross-sectional study. J Neurosurg 2017;127:1015–24. 10.3171/2016.8.JNS16707
    1. Tveiten OV, Carlson ML, Goplen F, et al. . Long-term auditory symptoms in patients with sporadic vestibular schwannoma: an international cross-sectional study. Neurosurgery 2015;77:218–27. 10.1227/NEU.0000000000000760
    1. Carlson ML, Tveiten Øystein Vesterli, Yost KJ, et al. . The minimal clinically important difference in vestibular schwannoma quality-of-life assessment: an important step beyond P < 0.05. Otolaryngol Head Neck Surg 2015;153:202–8. 10.1177/0194599815585508
    1. Carlson ML, Tveiten Øystein Vesterli, Driscoll CL, et al. . What drives quality of life in patients with sporadic vestibular schwannoma? Laryngoscope 2015;125:1697–702. 10.1002/lary.25110
    1. Carlson ML, Tveiten Øystein Vesterli, Driscoll CL, et al. . Risk factors and analysis of long-term headache in sporadic vestibular schwannoma: a multicenter cross-sectional study. J Neurosurg 2015;123:1276–86. 10.3171/2014.12.JNS142109
    1. Varughese JK, Wentzel-Larsen T, Pedersen P-H, et al. . Gamma knife treatment of growing vestibular schwannoma in Norway: a prospective study. Int J Radiat Oncol Biol Phys 2012;84:e161–6. 10.1016/j.ijrobp.2012.03.047
    1. Varughese JK, Wentzel-Larsen T, Vassbotn F, et al. . Analysis of vestibular schwannoma size in multiple dimensions: a comparative cohort study of different measurement techniques. Clin Otolaryngol 2010;35:97–103. 10.1111/j.1749-4486.2010.02099.x
    1. Myrseth E, Møller P, Pedersen P-H, et al. . Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. Neurosurgery 2005;56:927–35. 10.1055/s-2005-916493
    1. Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care 2005;20:187–91. 10.1016/j.jcrc.2005.04.005
    1. Begg C, Cho M, Eastwood S, et al. . Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637–9. 10.1001/jama.276.8.637
    1. Altman DG, Schulz KF, Moher D, et al. . The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663–94. 10.7326/0003-4819-134-8-200104170-00012
    1. Shaffer BT, Cohen MS, Bigelow DC, et al. . Validation of a disease-specific quality-of-life instrument for acoustic neuroma: the Penn acoustic neuroma quality-of-life scale. Laryngoscope 2010;120:1646–54. 10.1002/lary.20988
    1. Rowe J, Grainger A, Walton L, et al. . Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 2007;60:60–6. 10.1227/01.NEU.0000255492.34063.32
    1. Wolf A, Naylor K, Tam M, et al. . Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. Lancet Oncol 2019;20:159–64. 10.1016/S1470-2045(18)30659-4

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever